Tango Therapeutics Inc. jumped as much as 48% after initial results of a study showed a combination of its drug and a Revolution Medicines Inc. medicine shrunk tumors in advanced pancreatic cancer patients.

Merger arbitrage investors — fresh off a boom year for dealmaking — expect no let-up in the trend, with biotechnology firms seen as leading the pack among potential takeover candidates in the first quarter.